Ankylosing spondylitis susceptibility and severity - Contribution of TNF gene promoter polymorphisms at positions -238 and -308

Annals of the New York Academy of Sciences

Volumn 1173, Issue , 2009, Pages 581-588

  Sousa, Elsa ^a,b   Caetano Lopes, Joana ^a   Pinto, Patrícia ^a,c   Pimentel, Fernando ^d   Teles, José ^a,e   Canhão, Helena ^a,b   Rodrigues, Ana ^a,b   Resende, Catarina ^b   Mourão, Ana Filipa ^a,d   Ribeiro, Célia ^d   Pinto, Teresa Laura ^d   Rosa, Carlos Miranda ^b   Da Silva, José Alberto Pereira ^b   Branco, Jaime ^d   Ventura, Francisco ^c   Queiroz, Mário Viana ^b   Fonseca, João Eurico ^a,b  

^a UNIVERSITY OF LISBON   (Portugal)

^b HOSPITAL DE SANTA MARIA   (Portugal)

^c HOSPITAL DE SÃO JOÃO   (Portugal)

^d HOSPITAL EGAS MONIZ   (Portugal)

^e LUND UNIVERSITY   (Sweden)

Author keywords

Ankylosing spondylitis; Prognosis; Susceptibility; TNF promoter polymorphisms

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; GOLD SALT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR;

ADULT; ANKYLOSING SPONDYLITIS; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENE FREQUENCY; GENE LOCATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROMOTER REGION; RANDOMIZED CONTROLLED TRIAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 70049086655     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04758.x     Document Type: Conference Paper

References (39)

1. Khan, M.A. & E.J. Ball. 2002. Genetic aspects of ankylosing spondylitis. Best Pract. Res. Clin. Rheum. 16: 675-690.
2. Van Der Heijde, D. et al. 2005. Efficacy and safety of infliximab in patients with ankylosing spondyli-tis. Results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 52: 582-591.
3. Davis, J.C. Jr. et al. 2003. Enbrel ankylosing spondyli-tis study group. Recombinant human tumour necrosis factor receptor (etanercept) for treating ankylos-ing spondylitis: a randomized controlled trial. Arthritis Rheum. 48: 3230-3236.
4. Van Der Heijde, D. et al. 2006. Efficacy and safety of adalimumab in patients with ankylosing spondylitis. Results of a multicentre, randomized, doubleblind, placebo-controlled trial. Arthritis Rheum. 54: 2136.
5. Gratacos, J. et al. 1994. Serum Cytokines (IL-6, TNFalpha, IL-1beta and IFN-gama) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br. J. Rheumatol. 33: 927-931.
6. Lange, U. et al. 2000. Correlation between plasma TNF-alpha levels, IGF-1, biochemical markers of bone metabolism, markers of inflammation/disease activity, and clinical manifestations in ankylosing spondylitis. Eur. J. Med. Res. 5: 507-511.
7. Bal, A. et al. 2007. Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. Clin. Rheumatol. 26: 211-215.
8. Rudwaleit, M. et al. 2001. Low T cell production of TNFα and IFNγ in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 polymorphism. Ann. Rheum. Dis. 60: 36-42.
9. Braun, J. et al. 1995. Use of immunohistologic and in situ hybridization in the examination of sacroiliac joint biopsy from patients with ankylosing spondylitis. Arthritis Rheum. 38: 499-505.
10. Cavaleiro, J. & J.E. Fonseca. 2004. Gene do TNFα e artrite reumatóide: prognóstico e farmacogenética. Onde estamos e para onde vamos? Act Rheum. Port. 29: 233-242.
11. Braun, N. et al. 1996. Gene polymorphisms at position-308 of the tumor-necrosis-factor-alpha (TNFalpha) in multiple sclerosis and it's influence on the regulation of TNF-alpha production. Neurosci. Lett. 215: 75-78.
12. Van Heel, D.A. et al. 2002. Inflammatory bowel disease is associated with a TNF polymorphism that affects the interaction between the OCT1 and NF (kappa) B transcription factors. Hum. Mol. Genet. 11: 1281-1289.
13. Fonseca, J.E. et al. 2007. Contribution for new markers of rheumatoid arthritis activity and severity: sequencing of the tumor necrosis factor-alpha gene promoter. Arthritis Res. Ther. 9: R37.
14. Fabris, M. et al. (2002. Tumor necrosis factor-α gene polymorphisms in severe and mild rheumatoid arthritis. J. R h e u m a t . 29: 29-33.
15. Cvetkovic, J.T. et al. 2002. Susceptibility for and clinical manifestations of rheumatoid arthritis are associated with polymorphisms of the TNFalpha, IL-1beta and IL-1 Ra genes. 29: 212-219.
16. Mourão, A.F. et al. 2009. Tumour necrosis factor-alpha-308 genotypes influence inflammatory activity and TNF-alpha serum levels in children with Juvenile Idiopathic Arthritis. J. Rheumatol. 36: 837-842.
17. Balding, J. et al. 2003. Cytokine gene polymorphims: association with psoriatic arthritis susceptibility and severity. Arthritis Rheum. 48: 1408-1413.
18. Van Der Linden, S. et al. 1984. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 2: 361-368.
19. Garret, S. et al. 1994. A new approach to defining disease status in ankylosing spondilylitis: the Bath ankylosing spondylitis activity index. J. Rheumatol. 21: 2286-2291.
20. Calin, A. et al. 1994. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath ankylosing spondylitis functional index. J. Rheumatol. 21: 2281-2285.
21. Mackay, K. et al. 1998. The bath ankylosing spondyli-tis radiology index (BASRI). A new validated approach to disease assessment. Arthritis Rheum. 41: 2263-2270.
22. Wigginton, J.E. et al. 2005. A note on exact tests of Hardy-Weinberg equilibrium. Am. J. Hum. Genet. 76: 887-893.
23. Barrett, J.C. et al. 2005. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265.
24. Höhler, T. et al. 1998. Association of different tumor necrosis factor α promotor alleles frequencies with ankylosing spondylitis in HLA-B27 positive individuals. Arthritis Rheum. 41: 1489-1492.
25. Ming-Yuh, S. et al. 2007. Association of tumor necrosis factor α promoter polymorphisms with ankylosing spondylitis in Taiwan. Ann. Rheum. Dis. 66: 562-563.
26. Milicic, A. et al. 2000. Interethnic studies of TNF polymorphisms confirms the likely presence of a second MHC susceptibility locus in ankylosing spondylitis. Genes Immunity 1: 418-422.
27. Fraile, A. et al. 1998. Tumor necrosis factor gene polymorphisms in ankylosing spondylitis. Tissue Antigens 51: 386-390.
28. Lu, M.C. et al. 2008. Higher LPS-stimulated TNF-alpha mRNA levels in peripheral blood mononuclear cells from Chinese ankylosing spondylitis patients with-308(G/A) polymorphism in promoter region of tumor necrosis factor: association with distinct A33/B58/Cw10 haplotypes. Rheumatol. Int. 29: 189-195.
29. Vargas-Alarcon, G. et al. 2006. Tumor necrosis factor-alpha promotor polymorphims in Mexican patients with spondyloarthritis. Hum. Immunol. 67: 826-832.
30. Verjans, G.M. et al. 1994. Polymorphisms of the tumor necrosis factor alpha at position-308 in relation with ankylosing spondylitis. Clin. Exp. Immunol. 97: 45-47.
31. Gonzales, S. et al. 2001. TNF-238 promoter polymorphisms contributes to susceptibility to ankylosing spondylitis in HLA-B27 negative patients. J. R h e u m a-tol. 28: 1288-1293.
32. Brown, M.A. et al. 1998. A genome-wide screen for susceptibility loci in ankylosing spondylitis. Arthritis Rheum. 41: 588-595.
33. Laval, S.H. et al. 2001. Whole-genome screening in Ankylosing spondylitis: Evidence of non-MHC genetic-susceptibility loci. Am. J. Hum. Genet. 68: 918-926.
34. Brown, M.A. 2008. Breakthroughs in genetic studies of ankylosing spondylitis. Rheumatology 47: 132-137.
35. Pradeep, D.J. et al. 2008. Predicting outcome in ankylosing spondylitis. Rheumatology 47: 942-945.
36. Hammersma, J. et al. 2001. Is disease severity in ankylosing spondylitis genetically determined? Arthritis Rheum. 44: 1396-1400.
37. Khan, M.A. et al. 2007. The pathogenetic role of HLA-B27 and its subtypes. Autoimmun. Rev. 6: 183-189.
38. Zhao, L. et al. 2008. Identification of cytokines that might enhance the promoter activity of HLA-B27. J. Rheumatol. 35: 862-868.
39. Smith, A.J. et al. 2009. Cytokine and cytokine receptor gene polymorphisms and their functionality. Cytokine Growth Factor Rev. 20: 43-59.